DXVX Negotiates MTA for Room-Temperature Ultra-Long-Term mRNA Vaccine Platform with Major Global Pharmaceutical Company

DXVX announced on May 26 that it is currently negotiating a Material Transfer Agreement (MTA) with a major global pharmaceutical company for the out-licensing of its room-temperature, ultra-long-term storage mRNA vaccine platform.

Following recent MTA negotiations with a major domestic pharmaceutical company, additional discussions on the same platform technology are now underway with a global pharmaceutical company. This indicates that the interest of both domestic and international pharmaceutical and biotech companies is leading to concrete steps toward actual out-licensing.

The room-temperature, ultra-long-term storage mRNA vaccine platform, which is currently in the process of being out-licensed, was selected last year as a national project by ARPA-H. This platform is recognized for overcoming the limitations of mRNA vaccine technology and has attracted significant attention from pharmaceutical and biotech companies worldwide through global events such as the JP Morgan Healthcare Conference, leading to various ongoing negotiations for out-licensing.

DXVX's room-temperature, ultra-long-term storage mRNA vaccine platform enables the inherently unstable mRNA material to be stored at room temperature for up to 10 years. Lipid nanoparticles (LNPs) containing mRNA can be stored at room temperature in buffer solution for more than one month. The technology's value is further enhanced by its applicability to a wide range of fields, including not only mRNA but also RNA-based therapeutics, DNA vaccines, aptamers, gene therapies, and gene editing tools.

The Material Transfer Agreement is considered the most critical stage in the out-licensing process, as it involves direct verification and validation by the contracting party, resulting in a substantive technical evaluation. In the case of platform technologies, out-licensing contracts can be signed with multiple companies that require the technology. Accordingly, DXVX plans to conclude the negotiations and sign the MTA in the near future, while continuously expanding the pool of potential MTA partners for additional out-licensing opportunities.

Kwon Kyuchan, CEO of DXVX, stated, "Following our negotiations with a major domestic pharmaceutical company, the expansion of our MTA negotiations to include a major global pharmaceutical company demonstrates the continued global interest in our diverse technology assets. As we enter the final stages of the out-licensing process, we will do our utmost to deliver tangible results."